Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Tributyrin is a triglyceride form of butyric acid, a short-chain fatty acid (SCFA) naturally produced in the colon by microbial fermentation of dietary fibers. Scientific interest in tributyrin for Inflammatory Bowel Disorders (IBD), such as Crohn’s disease and ulcerative colitis, stems from the established role of butyrate in maintaining gut health. Butyrate is an important energy source for colonocytes (cells lining the colon), enhances intestinal barrier function, and exhibits anti-inflammatory properties by modulating immune cell activity and inhibiting pathways like NF-κB. Several preclinical studies have demonstrated that tributyrin supplementation can ameliorate colitis symptoms in animal models. It reduces inflammatory cytokines, limits mucosal damage, and promotes epithelial repair. Compared to free butyrate, tributyrin is more palatable and has better bioavailability, as it is gradually hydrolyzed in the gastrointestinal tract, delivering butyrate further along the colon. Human clinical data, however, are limited. Small pilot studies and some case reports suggest that butyrate enemas or oral butyrate (including tributyrin) may provide symptomatic relief and support mucosal healing in IBD patients, especially as adjunct therapy. Nonetheless, large-scale randomized controlled trials are lacking, and the evidence is not yet sufficient for mainstream clinical guidelines to recommend tributyrin as a primary treatment. In summary, tributyrin’s use in IBD is primarily supported by mechanistic and animal studies, with growing but still preliminary human evidence. Further research is needed to confirm its efficacy and safety in broader patient populations.

More about tributyrin
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by tributyrin

Products containing tributyrin